NCT07503236RecruitingNot Applicable
ENHANCE EFS: Early Feasibility Study (EFS) of the Nyra Cardiac Leaflet Enhancer (CARLEN) System
Nyra Medical, Inc.3 sites in 1 country30 target enrollmentStarted: July 2, 2026Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 30
- Locations
- 3
- Primary Endpoint
- Primary Endpoint
Study Overview
Brief Summary
Safety and performance evaluation of the CARLEN System in patients with functional mitral valve regurgitation.
Detailed Description
The purpose of this early feasibility study (EFS) is to evaluate the safety and performance of the CARLEN System in patients with symptomatic, moderate-to-severe or severe (MR ≥ 3+), functional (or secondary) mitral regurgitation.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 21 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age > 21 years at time of enrollment
- •Patient has provided informed consent, is willing and capable of participating in all testing, and agrees to return for all required post-procedure follow-up visits
- •Moderate-to-severe or severe (MR ≥ 3+) functional (secondary) mitral valve regurgitation
- •Symptomatic with mitral regurgitation (NYHA Class II, III, or ambulatory IV) despite maximally-tolerated guideline-directed medical therapy (GDMT) as determined by the local multidisciplinary Heart Team
- •Patient is suitable for transcatheter mitral valve repair as determined by the local multidisciplinary Heart Team and confirmed by the Eligibility Committee
Exclusion Criteria
- •Estimated life expectancy of less than 12 months
- •Women who are pregnant, lactating, or planning to become pregnant during the clinical study. Women of child-bearing potential must have negative pregnancy test result within 2 weeks prior to the procedure
- •Left Ventricular Ejection Fraction (LVEF) < 20%
- •Left ventricular end diastolic diameter (LVEDD) > 75 mm
- •Acute hemodynamic decompensation
- •Known hypersensitivity or contraindications to necessary and routine medications including contrast compounds or components used in the CARLEN System that cannot be successfully pre-medicated, including nitinol, an alloy of nickel and titanium
- •Contraindicated for transesophageal echo (TEE)
- •Presence of other anatomical characteristics and/or significant comorbidities that in the judgement of the Investigator or Eligibility Committee precludes the subject from participation
- •Aortic valve disease requiring intervention or intervention
- •Severe or greater tricuspid regurgitation
- •Severe right ventricular dysfunction
- •Severe pulmonary hypertension
- •Presence of significant congenital heart disease
- •Planned or scheduled cardiac surgery within next 12 months
- •Endocarditis within last 90 days
- •Evidence of intracardiac mass, vegetation, or inflammatory or infectious valve disease
Arms & Interventions
CARLEN System
Experimental
CARLEN System
Intervention: CARLEN System (Device)
Outcomes
Primary Outcomes
Primary Endpoint
Time Frame: 30-days post-procedure
Freedom from device- or procedure-related serious adverse events through 30-days post-procedure
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (3)
Loading locations...
Similar Trials
Not yet recruiting
Phase 2
Swedish Cardiac And Renal Failure study-1 (SCARF-1): An open-label pilot trial to evaluate the feasibility, safety and efficacy of eplerenone in patients with heart failure with reduced ejection fraction and severe chronic kidney disease.2025-520550-11-00Karolinska Institutet40
Not yet recruiting
Not Applicable
Heart function assessment in chronic liver disease patientsCTRI/2024/08/072160Department of cardiology169
Recruiting
Not Applicable
FIH ITA Study - Vesalius TMVr System for Symptomatic Degenerative Mitral RegurgitationNCT07470788Vesalius Cardiovascular Inc.5
Recruiting
Phase 1
The REValve Clinical Trial an Evaluation Of the ReValve Palmetto Valve for the Replacement of the Native Mitral VaLVEMitral RegurgitationNCT07450911ReValve Solutions Inc.20
Not yet recruiting
Not Applicable
Pivotal Study of the Vienna Aortic Valve SE SystemCTRI/2025/10/096465P+F Products + Features GmbH267